Clinical Trials
29 trialsPTC-Guided Atorvastatin Plus Axitinib and Toripalimab in Advanced RCC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Pfizer
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Pfizer
Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer
University of Southern California
A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)
National Cancer Institute (NCI)
Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma
Fox Chase Cancer Center
EVAX
University Hospital, Bordeaux
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
Hoffmann-La Roche
SLM + Axitinib for Clear Cell RCC
University of Iowa
SAMURAI
NRG Oncology
NEOPAX
University of Colorado, Denver
A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma
West China Hospital
Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell Carcinoma
Qilu Hospital of Shandong University
SPARCC
Dana-Farber Cancer Institute
Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma
Sun Yat-sen University
An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Yonsei University
Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC
H. Lee Moffitt Cancer Center and Research Institute
Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer
SWOG Cancer Research Network
KEYNOTE-426
Merck Sharp & Dohme LLC
Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy
Tianjin Medical University Cancer Institute and Hospital
Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab
University of Iowa
International Multicentric Study ARON-1
Hospital of Macerata
Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery
University of California, San Francisco
A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
PADRES
University of California, San Diego
Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC
Tianjin Medical University Second Hospital
Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
Peking Union Medical College Hospital
JAVELIN Renal 101
Pfizer
A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma
MedImmune LLC